Study of cytokeratin 7 expression in papillary thyroid carcinoma and its correlation with some prognostic factors

Document Type : Original Article

Authors

Department of Pathology and Anatomical Sciences, Faculty of Medicine, Shahed University, Tehran, Iran

Abstract

Background and Objective: Prognosis of papillary thyroid carcinoma is associated with age, sex, tumor size, lymph node metastasis, capsule invasion, multifocality, and history of radiation. Today, for prognostic evaluation of different tumors, various markers such as cytokeratin 7 are used. So, in this study our aim was evaluation of cytokeratin 7 expressions in papillary thyroid carcinoma and its correlation with prognostic factors.
Materials and Methods: In this cross-sectional study, 87 paraffin blocks from patients with papillary thyroid carcinoma referred to Mostafa Khomeini hospital were evaluated for Cytokeratin7 expression by immunohistochemistry method. Expression of this marker was determined as poor (+), moderate (++), strong (+++) and severe (++++). Then the association of cytokeratin 7 with some prognostic factors was evaluated
Results: The patient's mean age was 40.13± 16.97 and 87.4% of patients were female. Cytokeratin 7 expression was seen in all samples. 86.2% of samples showed poor and moderate expression and 13.8% of them showed strong and severe expression. Reduced expression of cytokeratin 7 was significantly associated with an increase in age and lymph node involvement but was not associated with sex, tumor size, and capsule invasion.
Conclusion: Cytokeratin 7 expression is prevalent in papillary thyroid carcinoma samples and it is associated with lymph node involvement but it is not associated with tumor size and capsule invasion as important prognostic factors in papillary thyroid carcinoma. So, definite conclusion in this regard needs long-term studies.

Keywords

References

  1. Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer: Epidemiology and risk factors. Journal of Endocrinological Investigation 2012; 35(6): 3-9. PMID: 23014067.

 

  1. Cancer office. 2009-2010 National cancer report. Tehran: Ministry of Health and Medical Education; 2013.

 

  1. Abdullah MI, Junit SM, Leong K, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer: Genetic Alterations and molecular biomarker investigations. International Journal of Medical Science 2019; 16(3):450-460. doi: 10.7150/ijms.29935.

 

  1. Jalali Nadoushan MR, Davati A, Hassanpour M. Relation between E-Cadherin expressions in papillary thyroid carcinoma with some prognostic factors. Quarterly of Horizon of Medical Science 2014; 19 (4):192-196.

 

  1. Rosai J. Rosai and Ackerman's surgical pathology. 11th Ed. New York: Mosby; 2017.

 

  1. Cao J, Chen C, Wang QL, Gee MH. Clinicopathological features and prognosis of familial papillary thyroid carcinoma- a large- scale, matched, case control study. Clinical Endocrinology 2016; 84(4):598-606. doi: 10.1111/cen.12859.

 

  1. Kumar A, Jagannathan N. Cytokeratin: A review on current concepts. International Journal of Orofacial Biology 2018; 2(1): 6-11. doi: 10.4103/ijofb.ijofb_3_18.

 

  1. Selves J, Long-Mira E, Mathieu MC, Rochaix P, IIie M. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers 2018; 10(4):108. doi: 10.3390/cancers10040108.

 

  1. Ordonez NG. Broad-spectrum immunohistochemical epithelial markers: A review. Human Pathology 2013; 44(7):1195-215. doi: 10.1016/j.humpath.2012.11.016.

 

  1. Luo HT, Liang CX, Luo RC, GU WG. Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer. Bioscience Reports 2017; 37(6):BSR20171086. doi: 10.1042/BSR20171086.

 

  1. Yun SP, Seo HI. Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. BMC Gastroenterology 2015; 15:165. doi: 10.1186/s12876-015-0396-x.
  2. Xu Y, Wang W, Li L, Liu J, Wu X, Yu J, et al. FOXA1 and CK7 expression in esophageal squamous cell carcinoma and its prognostic significance. Neoplasma 2018; 65(3):469-476. doi: 10.4149/neo_2018_170529N384.

 

  1. Jalali Nadoushan MR, Siadati S, Davati A, Torabi Parizi G, Ghasemi S. Cytokeratin 7 expression in gastric and colorectal adenocarcinoma: Correlation with prognostic factors. Caspian Journal of Internal Medicine 2015; 6(4): 229-232. PMCID: PMC4649273.

 

  1. Fei F, Li C, Cao Y, Liu K, Du J, Gu Y, et al. CK7 expression associates with the location, differentiation, lymphnode metastasis and the Dukes stage of primary colorectal cancers. Journal of Cancer 2019; 10(11):2510-2519. doi: 10.7150/jca.29397. eCollection 2019.

 

  1. Kaliszewski K, Diakowska D, Strutynska-Karpinska M, Rzeszutko M, Grzegrzolka J, Dziegiel P, et al. Expression of cytokeratin-19 in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region. Folia Histochemica Cytobiologica 2016; 54(4):193-201. doi: 10.5603/FHC.a2016.0025.

 

  1. Dencic T, Cvejic D, Paunovic I, Tatic S, Havelka M, Savin S. Cytokeratin 19 expression discriminates papillary thyroid carcinomas from other thyroid lesions and predicts its aggressive behavior. Medical Oncology2013;30(1):362. doi: 10.1007/s12032-012-0362-1.

 

  1. Abdou AG, Shabaan M, Abdallha R, Nabil N. Diagnostic value of TROP-2 and CK19 expression in papillary thyroid carcinoma in both surgical and cytological specimens. Clinical Pathology 2019; 12:2632010X19863047. doi: 10.1177/2632010X19863047.

 

  1. Calanjiu CM, Simionescu CE, Stepan AE, Cernea D, Zavoi RE, Margaritescu C. The expression of CK19, Vimentin and E-Cadherin in differentiated thyroid carcinomas. Romanian Journal of Morphology and Embryology 2014; 55(3): 919-925.
  2. Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. Archives of Pathology and Laboratory Medicine 2015; 139(1):67-82. doi: 10.5858/arpa.2014-0056-RA.

 

  1. Jalali nadoushan MR, Heshmati M, Gholami Kelishomi S. Comparison of expressioin of cytokeratin 7 on epithelium of nasal polyps and mucosa of chronic rhinosinusitis. Journal of Basic and Clinical Pathophysiology 2015; 3(2): 1-4. doi:10.22070/JBCP.2015.223

 

  1. Liu LZ, Yang LX, Zheng BH, Dong P, Liu XY, Wang Z, et al. CK7/CK19 index: A potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients. Journal of Surgical Oncology 2018; 117(7):1531-1539. doi: 10.1002/jso.25027.

 

  1. Kim HJ, Kim YS, Kim SW, Kim KC. Expression of Cyclin D1, Cytokeratin 7, Cytokeratin 20 and Vimentin in papillary thyroid cancer and relationship with patient’s prognostic factors. The Korean Journal of Endocrine Surgery 12(2):92-96. doi:10.16956/kjes.2012.12.2.92.

 

  1. Heshmati M, Jalali nadoushan MR, Jafari F, Moradi F. Relationship between CD10 expression with some prognostic factors of papillary thyroid carcinoma. Journal of Advances in Medical and Biomedical Research 2017; 25(109): 120-129.

 

  1. Jalali nadoushan MR, Sarmastzadeh T, Davati A. Comparision of BAX expression in papillary carcinoma and papillary microcarcinoma of thyroid and its relationship with prognostic factors. Scientific Journal of Kurdistan University Medical Sciences 2017; 22(87):43-49.
  2. Marecko I, Cvejic D, Selemetjev S. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croatain Medical Journal 2014; 55(2):128-137. doi: 10.3325/cmj.2014.55.128.
  3. Liu X, Su C, Xu J, Zhou D, Yan H, Li W, et al. Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis. Oncology Letters 2019; 17(2):2308-2316. doi: 10.3892/ol.2018.9850.
Daneshvar Medicine
Volume 29, Issue 2 - Serial Number 153
July and August 2021
Pages 91-99

Files

Share

How to cite

Statistics